Effects of a new liver support system in patients with acute-on-chronic liver failure
The Effects of Double Plasma Molecular Adsorption System in Acute on Chronic Liver Failure Patients
This study tests whether a new liver support system can help patients with acute-on-chronic liver failure recover better and live longer by cleaning their blood.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chulalongkorn University Academic / other |
| Locations | 1 site (Bangkok) |
| Trial ID | NCT05030571 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of a Double Plasma Molecular Adsorption System (DPMAS) in patients suffering from acute-on-chronic liver failure. The DPMAS aims to remove harmful cytokines and bilirubin from the blood, potentially improving immune function and reducing mortality rates. Patients will receive standard treatment alongside DPMAS to evaluate its effectiveness in enhancing recovery. The study focuses on patients admitted to intensive care units who meet specific diagnostic criteria.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with acute-on-chronic liver failure who are admitted to an intensive care unit.
Not a fit: Patients who are pregnant, have received steroid treatment, or are expected to die within 24 hours may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce mortality rates and improve recovery outcomes for patients with acute-on-chronic liver failure.
How similar studies have performed: Other studies have shown promise with similar liver support systems, but the specific application of DPMAS in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18 or more 2. Diagnosis of Acute ontop chronic liver failure by Asian Pacific association for the study of the liver (APASL) criteria 3. Admitted to intensive care unit Exclusion Criteria: 1. Pregnancy 2. Received steroid treatment 3. Expected dead within 24 hour 4. WBC \< 500/mm3 5. Allergy to DPMAS 6. History of organ transplant 7. Terminal illness with do not resuscitation order
Where this trial is running
Bangkok
- King Chulalongkorn Memorial Hospital — Bangkok, Thailand (Recruiting)
Study contacts
- Study coordinator: Phatadon Sirivongrangson, MD
- Email: phatadon@hotmail.com
- Phone: (+66)0852447788
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.